Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
N/A
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
SpyGlass Pharma, Inc. Common Stock
Market Cap
$828.48M
Net Profit Margin
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833.81M
Net Profit Margin
-560.85%
TTM Avg
-63.69%
3Y Avg
-31.84%
5Y Avg
-21.23%
Market Cap
$838.16M
Net Profit Margin
-61.32%
TTM Avg
-78.55%
3Y Avg
-9174.62%
5Y Avg
-9174.62%
Market Cap
$838.62M
Net Profit Margin
-82.49%
TTM Avg
-271.33%
3Y Avg
-235.13%
5Y Avg
-173.69%
Market Cap
$817.67M
Net Profit Margin
-12.35%
TTM Avg
-13.43%
3Y Avg
-52.20%
5Y Avg
-503.49%
Market Cap
$816.13M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$852.35M
Net Profit Margin
-173.85%
TTM Avg
-104.63%
3Y Avg
-54.62%
5Y Avg
-54.62%
Market Cap
$853.13M
Net Profit Margin
116.30%
TTM Avg
67.23%
3Y Avg
16.07%
5Y Avg
4.15%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $828.48M | 0.00% | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | -560.85% | -63.69% | -31.84% | -21.23% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | -61.32% | -78.55% | -9174.62% | -9174.62% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | -82.49% | -271.33% | -235.13% | -173.69% |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | -12.35% | -13.43% | -52.20% | -503.49% |
| Jade Biosciences, Inc. (JBIO)vs › | $816.13M | 0.00% | 0.00% | 0.00% | 0.00% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | -173.85% | -104.63% | -54.62% | -54.62% |
| InMode Ltd. (INMD)vs › | $804.16M | 20.69% | 35.62% | 36.75% | 38.26% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 116.30% | 67.23% | 16.07% | 4.15% |
| Alumis Inc. (ALMS)vs › | $855.38M | -5933.45% | -505.88% | -252.94% | -252.94% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
